HGH Fragment 176-191 vs Dulaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Frag 176-191, HGH Frag
HGH Fragment 176-191 is exactly what it sounds like: a short tail-end piece of the human growth hormone molecule, amino acids 176 through 191. The idea was to keep the fat-burning part of growth hormone while ditching the parts that raise blood sugar and IGF-1. The optimized drug version, AOD-9604, actually went through real human trials for obesity, and the blunt result is that it was very safe but did not produce meaningful weight loss.
Also: Trulicity
Dulaglutide (brand name Trulicity) is a once-weekly injectable GLP-1 receptor agonist made by fusing a modified GLP-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. It is FDA-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. The once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents.
Key Comparison Insights
- Dulaglutide is FDA approved, while HGH Fragment 176-191 remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Dulaglutide has stronger research evidence (FDA Approved) compared to HGH Fragment 176-191 (Human Trials).
Detailed Comparison
| Attribute | HGH Fragment 176-191 | Dulaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | This fragment is the C-terminal portion of growth hormone, the segment researchers identified as carrying its lipolytic (fat-breakdown) activity. In lab and animal work it stimulates fat cells to release and burn fat, increasing glycerol output and fat oxidation, apparently without binding the growth hormone receptor itself. That is the selling point: because it does not act on the GH receptor, it does not raise IGF-1, does not promote tissue growth, and does not impair glucose handling the way full growth hormone can. Some research points to involvement of beta-3 adrenergic signaling in fat tissue, though the exact human mechanism is not fully nailed down. | Dulaglutide activates the GLP-1 receptor, mimicking the natural incretin hormone your gut releases after eating. It prompts glucose-dependent insulin release, suppresses glucagon, and slows gastric emptying, so blood sugar drops after meals without driving dangerous lows. The antibody (Fc) portion bolted onto the peptide makes the molecule too large for the kidneys to quickly clear and shields it from the DPP-4 enzyme that destroys natural GLP-1 within minutes. That engineering is the entire reason a once-weekly schedule works. The appetite and modest weight effects come from the same GLP-1 signaling in brain regions that regulate hunger. |
| Common Dosing | 250-500 mcg daily 1-2x daily, fasted | 1.5-4.5 mg weekly Once weekly |
| Administration | Subcutaneous injection on empty stomach | Subcutaneous injection weekly |
| Typical Duration | 8-12 weeks | Long-term / chronic use |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The animal data looked promising and the human data deflated it, which is the whole story here. In obese mice (International Journal of Obesity, 2001), both growth hormone and AOD-9604 reduced body-weight gain and increased fat oxidation, without the blood-sugar problems of full GH. A small 12-week phase 2 human study generated the famous early headline, with the 1 mg group losing about 2.8 kg versus 0.8 kg on placebo. But the larger, better-powered phase 2b trial of roughly 500 obese adults over 24 weeks failed to show a significant weight-loss advantage over placebo, and the developer abandoned obesity development. What survived is the safety record: across about six trials and roughly 900 people, AOD-9604 was as well tolerated as placebo, with no IGF-1 rise and no glucose effects (Journal of Endocrinology and Metabolism, 2013). So it is safe and it does not work as a meaningful fat-loss drug in humans. | Dulaglutide is backed by extensive human trials, not animal models. The AWARD program established its glucose-lowering efficacy across many type 2 diabetes settings. The landmark REWIND trial, published in The Lancet in 2019, followed over 9,900 patients for a median of more than five years and was unusual because most participants (about 69%) had no prior cardiovascular disease. It found dulaglutide reduced major cardiovascular events (cardiovascular death, heart attack, or stroke) versus placebo, 12.0% vs 13.4%, a hazard ratio of 0.88. That made it one of the first GLP-1 agents with evidence supporting both primary and secondary cardiovascular prevention. The typical downsides are gastrointestinal (nausea, diarrhea), and like others in the class it carries a boxed warning about thyroid C-cell tumors based on rodent data. |
Frequently Asked Questions: HGH Fragment 176-191 vs Dulaglutide
What is the difference between HGH Fragment 176-191 and Dulaglutide?
HGH Fragment 176-191 is a weight loss peptide that hgh fragment 176-191 is exactly what it sounds like: a short tail-end piece of the human growth hormone molecule, amino acids 176 through 191. the idea was to keep the fat-burning part of growth hormone while ditching the parts that raise blood sugar and igf-1. the optimized drug version, aod-9604, actually went through real human trials for obesity, and the blunt result is that it was very safe but did not produce meaningful weight loss. Dulaglutide is a weight loss peptide that dulaglutide (brand name trulicity) is a once-weekly injectable glp-1 receptor agonist made by fusing a modified glp-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. it is fda-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. the once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents. The main differences lie in their mechanisms of action and clinical applications.
Which is better, HGH Fragment 176-191 or Dulaglutide?
Neither is universally "better" - the choice depends on your specific goals. HGH Fragment 176-191 is typically used for weight loss purposes, while Dulaglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can HGH Fragment 176-191 and Dulaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using HGH Fragment 176-191 and Dulaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.